News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:01:40 2025-01-14 am EST			5-day change	1st Jan Change
55.70 ^USD	+0.62%		-2.70%	-1.71%

07:58am	Lannebo Sverige Plus increased 1.5 percent in December - holdings in SEB, Essity and Swedbank reduced	FW
Jan. 13	Lannebo Sweden increased 0.5 percent in December - global license agreement for BioArctic	FW

Lannebo Sverige Plus increased 1.5 percent in December - holdings in SEB, Essity and Swedbank reduced	01:58am	FW
Lannebo Sweden increased 0.5 percent in December - global license agreement for BioArctic	Jan. 13	FW
Bristol-Myers Squibb Company Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 07:30 AM	Jan. 13
Bristol-Myers Squibb Company Exercises Exclusive License Option for ArsenalBio's AB-4000 Series	Jan. 13	MT
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors	Jan. 13	AQ
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year	Jan. 13	AQ
Annexon, Inc. Appoints William ?BJ? Jones to Its Board of Directors	Jan. 10	CI
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $52 From $53, Maintains Neutral Rating	Jan. 10	MT
Truist Raises Price Target on Bristol-Myers Squibb to $65 From $62, Keeps Buy Rating	Jan. 08	MT
Bristol Myers Squibb Announces FDA Approval of Cobenfy	Jan. 08	CI
Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference	Jan. 06	AQ
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference	Jan. 03	BU
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Jan. 03	MT
Ex-dividend day	Jan. 02	FA
Ex-dividend day	Jan. 02	FA
Lexicon Pharmaceuticals, Inc. Appoints Scott M. Coiante as Senior Vice President	Jan. 02	CI
Lexicon Pharmaceuticals, Inc. Announces CFO Changes	Jan. 02	CI
European Equities Close Mostly Higher in Tuesday Trading; EU Withholds Over $1 Billion From Hungary	Dec. 31	MT
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Dec. 31	MT
Bristol Myers Squibb - U.S. Food and Drug Administration Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications	Dec. 30	AQ
Bristol Myers: Opdivo Qvantig approved for subcutaneous use	Dec. 30	CF
US FDA Clears Injectable Form of Bristol Myers Squibb's Cancer Medication	Dec. 29	MT
Bristol Myers Squibb Receives FDA Approval for Cancer Treatment	Dec. 27	DJ
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2	Dec. 27	BU
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig?? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications	Dec. 27	CI

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST